Trethera
  • Home
  • About Us
  • Technology
  • Pipeline
  • Media
    • News
    • Publications
  • Contact
  • Menu

News

Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients

17th March 2023/in News /by Trethera

Los Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, received a unanimous recommendation from the independent safety review committee (“SRC”) to continue clinical trial advancement of Trethera’s lead development asset, TRE-515, its first-in-class deoxycytidine […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-03-17 15:06:112023-03-17 18:59:26Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients

Trethera Announces Appointment of Laurent Dubois to Board of Directors

16th February 2023/in News /by Trethera

Los Angeles, February 15, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Laurent Dubois to the Trethera Board of Directors as an independent director.  A healthcare executive veteran with over two decades of […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-02-16 00:34:122023-02-16 00:34:12Trethera Announces Appointment of Laurent Dubois to Board of Directors

Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

24th January 2023/in News /by Trethera

Los Angeles, January 24, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 8th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).  Dr. Peter M. […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-01-24 01:47:292023-01-25 15:06:57Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors

24th January 2023/in News /by Trethera

Los Angeles, January 18, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Boyd Quinnell, CPA, MBA, to the Trethera Board of Directors as an independent director.  A veteran healthcare executive with over 30 […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-01-24 01:31:522023-01-24 01:35:35Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors

Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program

20th October 2022/in News /by Trethera

Los Angeles, October 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), has awarded Trethera a $1.6 million Fast-Track STTR […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2022-10-20 02:08:132022-10-20 02:13:38Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program
Page 1 of 512345